Dr. Brian Francis Chapin, MD

Dr. Chapin practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Chapin's NPI, 1104952571, was assigned on February 27, 2007. Dr. Chapin graduated from Georgetown University School Of Medicine in 2004. Dr. Chapin holds Texas license N6214.

Dr. Chapin's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Chapin's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chapin practices. Vendor and product names are available with a free account.

Urology is Dr. Chapin's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Chapin is board certified in urology by the American Board of Urology. Dmand AI has Dr. Chapin's licenses on file in 11 states: Texas, Florida, Arizona, Tennessee, Washington, Alabama, Georgia, Louisiana, Mississippi, Oklahoma and Massachusetts.

Dmand AI lists prostate surgery, urinary endoscopy and urinary tract infection among the conditions Dr. Chapin treats.

CMS data shows 89 Medicare services from Dr. Chapin across 3 procedure codes in 2024, for 93 Medicare patients. Medicare paid $21,406 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 93 Medicare patients who saw Dr. Chapin in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 0.80, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chapin's median patient age at 70, with 0% women.

In 2024, Dr. Chapin wrote 14 Medicare Part D claims. 93% of them were for generic drugs. They cover 1 drug, with $15 in total drug cost. In 2020, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Chapin for performance year 2024, reported as part of a group. Dr. Chapin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chapin as offering telehealth. CMS counts 27 procedures of prostate resection by Dr. Chapin, more than 89% of the clinicians it reports for that procedure.

Hernia repair (minimally invasive): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 106 papers to Dr. Chapin, published from 2011 to 2025. 2020 was the busiest year, with 16. The most frequent topics are Prostatic Neoplasms, Prostatectomy and Prostate-Specific Antigen. Dr. Chapin has published most often in Eur Urol. Dr. Chapin's most frequent co-authors are John W. Davis, MD, Chad Tang, MD and Tharakeswara Kumar Bathala, MD.

Dmand AI links Dr. Chapin to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Neoplasm Metastasis, Prostatic Neoplasms and Neoplastic Processes. M.D. Anderson Cancer Center sponsors the most, 2.

CMS Open Payments shows 110 general payments to Dr. Chapin from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 47% of the total. Genentech, Inc. paid the most, $14,888.

Dr. Chapin graduated from Georgetown University School Of Medicine in 2004.

Dr. Chapin is in network with 15 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.